Metropolis Healthcare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Metropolis Healthcare Ltd filed with BSE on 02 Sept 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Metropolis Healthcare presented its business strategy, growth engines, and margin ambitions at an Investor and Analyst Meet, reporting FY26 revenue of Rs 1,646 crore and a three-year revenue CAGR of 17.6%. Management described plans to expand specialty testing, genomics, TruHealth bundles, and a new radiology mini-hub format, while maintaining a medium-term revenue growth guidance of 14%-15% delivered at 17% in the most recent quarter. Management also discussed margin improvement plans, targeting EBITDA margin expansion from 24.4% toward 27%-28% through mix improvement, productivity, and network utilization.
Numbers mentioned
Revenue: INR1,646 crores (FY26)
p. 4
“We ended last year with a revenue of INR1,646 crores, which is coming from B2C and B2B.”
Ameera Shah, page 4 of the filed PDF · View the filing
Revenue CAGR: 17.6% (last three years)
p. 8
“We've had a 17.6% CAGR from a revenue perspective.”
Ameera Shah, page 8 of the filed PDF · View the filing
Revenue CAGR: 23.6% (FY26)
p. 8
“And of course, in FY’26, we had 23.6% CAGR.”
Ameera Shah, page 8 of the filed PDF · View the filing
EBITDA CAGR: 18.6% (last three years)
p. 8
“Our EBITDA has also Metropolis Healthcare Limited August 27, 2026 Page 8 of 34 grown at about 18.6% CAGR for three years and last year was 23% and the same thing with PAT, very similar numbers.”
Ameera Shah, page 8 of the filed PDF · View the filing
EBITDA margin: 24.4% (FY26)
p. 9
“And while the margin was 24.4% last year, actually it was 25.9%, because the organic margin, EBITDA margin of Metropolis because it showed a little bit lower because of the acquisition we did last year”
Ameera Shah, page 9 of the filed PDF · View the filing
Number of laboratories: 209
p. 3
“currently we have 209 laboratories and 5,000 plus centers.”
Ameera Shah, page 3 of the filed PDF · View the filing
B2C revenue share: 57%
p. 4
“So of this entire business, about 57% of our revenue comes from B2C.”
Ameera Shah, page 4 of the filed PDF · View the filing
Specialty revenue share: 42%
p. 8
“Now today, if we look at it, Metropolis has approximately, I think 42%, if I'm not mistaken of our business coming from specialty”
Ameera Shah, page 8 of the filed PDF · View the filing
Revenue growth: 17% (Q1)
p. 21
“but we delivered 17% in the last quarter”
Surendran Chemmenkotil, page 21 of the filed PDF · View the filing
EQAS quality score: 99.99%
p. 8
“we have a 99.99%, right, EQAS score, which means that we are pretty much in the top 1% of labs in the world when it comes to our quality.”
Ameera Shah, page 8 of the filed PDF · View the filing
Dividend payout: 22% of PAT (last year)
p. 10
“Last year we did a dividend of about 22% of PAT.”
Ameera Shah, page 10 of the filed PDF · View the filing
International business revenue contribution: less than 10%
p. 32
“Less than 10% at this point.”
Ameera Shah, page 32 of the filed PDF · View the filing
North India revenue contribution: 18%
p. 32
“So going forward, how do you think like it will change like in the next 3-4 years?”
Sahil, page 32 of the filed PDF · View the filing
Digital channel revenue contribution: 25%
p. 13
“Today, 25% of my business actually come from digital initiatives, and digital platforms are like my app, my website, my customer data platform, and so on and so forth.”
Surendran Chemmenkotil, page 13 of the filed PDF · View the filing
Home collection revenue contribution: 11%-12%
p. 15
“The other is the channel of home collection. That's roughly around 11%-12% of our revenues today”
Mohan Menon, page 15 of the filed PDF · View the filing
TruHealth revenue contribution: close to 20%
p. 12
“We have roughly close to 20% of our business is today TruHealth, right?”
Surendran Chemmenkotil, page 12 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 14%-15% · medium term
stated firmly by Surendran Chemmenkotil
p. 21
“I just wanted to mention this, you know, last, you know, meetings in the investor meeting or the earnings call, we mentioned that for the medium term we are talking about a 14 to 15 percentage guidance.”
Surendran Chemmenkotil, page 21 of the filed PDF · View the filing
Revenue growth guidance for next few quarters — 14%,15% · next 3-4 quarters
stated conditionally by Surendran Chemmenkotil
p. 27
“But I think I would suggest at this point of time, keep the guidance when maybe, maybe in the next 3, 4 quarters at 14%, 15%.”
Surendran Chemmenkotil, page 27 of the filed PDF · View the filing
EBITDA margin — 27% to 28% · next 2-3 years
stated as an aspiration by Sameer Patel
p. 22
“if you see the ambition is to improve our EBITDA margin from 24.4% to 27% to 28%”
Sameer Patel, page 22 of the filed PDF · View the filing
Center-to-lab ratio — 1:35 · next couple of years
stated as an aspiration by Surendran Chemmenkotil
p. 12
“We plan to take this ratio from 1:24 to 1:35.”
Surendran Chemmenkotil, page 12 of the filed PDF · View the filing
Radiology mini-hubs — about 100 mini hubs · next couple of years
stated conditionally by Surendran Chemmenkotil
p. 14
“and we'll come up with about 100 labs in the next couple of years -- 100 mini hubs in the next couple of years”
Surendran Chemmenkotil, page 14 of the filed PDF · View the filing
Working capital — single digit
stated as an aspiration by Sameer Patel
p. 23
“So, our aspiration is to take our working capital to a single digit from currently the double-digit working capital.”
Sameer Patel, page 23 of the filed PDF · View the filing
Core Diagnostics EBITDA — company level EBITDA margins · year 3 post-acquisition
stated as an aspiration by Surendran Chemmenkotil
p. 20
“1 year after acquisition, this is high single-digit EBITDA and we are now, I was guiding everyone that, maybe year 3 we will be close to the company levels of EBITDA.”
Surendran Chemmenkotil, page 20 of the filed PDF · View the filing
North India revenue contribution — 25% · next few years
stated conditionally by Ameera Shah
p. 32
“If I have to assume that North India is going to grow a little bit faster than everything else, then the contribution will move probably from 18% to 25% in the next few years.”
Ameera Shah, page 32 of the filed PDF · View the filing
Radiology center rollout — first 50 centers in year 1, next 50 in following year · next 2 years
stated conditionally by Surendran Chemmenkotil
p. 26
“So, we will experiment with first maybe 50 centers in year 1.”
Surendran Chemmenkotil, page 26 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said there is natural operating leverage but reinvestment cycles will continue, and the goal is not to maximize margin percentage but to stay relevant and invest for growth.
Answered by Ameera Shah
Asked by Kunal Thanvi: What long-term operating margin should investors expect for the business given high gross margins?
p. 26
“So, I think keeping in mind a long-term vision for the business, I don't think the goal is just to keep maximizing profit margin.”
Ameera Shah, page 26 of the filed PDF · View the filing
Management estimated roughly Rs 35-40 lakhs per center investment and said productivity could rise 2x-3x with corporate business layered in.
Answered by Surendran Chemmenkotil
Asked by Tausif Shaikh: What capex is planned for the 100 radiology labs/centers and what revenue contribution is expected?
p. 26
“So, roughly about INR35 lakhs-INR40 lakhs per investment would be good enough for us to run a good mini, you know, hubs, you know, to start with.”
Surendran Chemmenkotil, page 26 of the filed PDF · View the filing
Management said it is too early to give FY28 guidance and suggested maintaining the 14%-15% guidance for the next several quarters without price increases factored in.
Answered by Surendran Chemmenkotil
Asked by Tausif Shaikh: How should FY28 growth guidance be viewed, given potential price hikes and radiology contribution?
p. 27
“But I think I would suggest at this point of time, keep the guidance when maybe, maybe in the next 3, 4 quarters at 14%, 15%. I mean, without price increase.”
Surendran Chemmenkotil, page 27 of the filed PDF · View the filing
Management said many available assets do not fit their acquisition criteria and that they prefer suboptimal but scalable businesses at reasonable prices rather than paying high multiples.
Answered by Ameera Shah
Asked by Ronak: What kind of M&A consolidation opportunities does Metropolis see in the market?
p. 27
“These are suboptimal businesses from a margin perspective but they could make money and decent good money within a system like ours but standalone like they are probably not going to make money.”
Ameera Shah, page 27 of the filed PDF · View the filing
Management said they are still evaluating multiple ideas and do not yet have a clear blueprint, but see potential for a serious business over a five-year horizon.
Answered by Ameera Shah
Asked by Ronak: Does Metropolis see an opportunity to build a chain of clinics beyond diagnostics?
p. 28
“So I think we will still be probably a couple of quarters out, but I do certainly see if I look at it from a 5-year basis, we are not going to do something that's just going to give us an additional INR20,000 to pay the rent for our property per month.”
Ameera Shah, page 28 of the filed PDF · View the filing
Management said Tier 3 centers focus on semi-specialty and specialty tests rather than routine tests, and specialty pricing is uniform nationally so Tier 3 unit economics are comparable or better than metros.
Answered by Ameera Shah
Asked by Ashutosh: How does test mix and unit economics evolve as Metropolis expands into Tier 2 and Tier 3 cities?
p. 30
“So from a unit economics basis, you are making equally or better margins in Tier 3 compared to a metro.”
Ameera Shah, page 30 of the filed PDF · View the filing
Management said they do not plan to enter advanced radiology like MRI/CT as a core strategy, citing different ROIC and governance concerns, though limited preventive-health experiments may occur.
Answered by Ameera Shah
Asked by Ashutosh: Would Metropolis pursue MRI/CT scale radiology centers combined with pathology in future?
p. 31
“So we feel it compromises our position. But we may experiment, let's say, on the preventive healthcare space.”
Ameera Shah, page 31 of the filed PDF · View the filing
Management said the company does not engage in doctor referral commissions, relying instead on quality and science to generate referrals.
Answered by Ameera Shah
Asked by Sahil: How does Metropolis manage doctor referrals and commissions when entering new areas?
p. 32
“So, doctor referrals and commissions in India are actually, not legal and not recommended even from a tax perspective.”
Ameera Shah, page 32 of the filed PDF · View the filing
Management said pathology testing has low frequency of use compared to other in-home services, limiting overlap with such platforms, though partnerships remain a future possibility.
Answered by Ameera Shah
Asked by Kunal Thanvi: Is Metropolis considering partnerships with in-home service platforms for distribution?
p. 34
“So fundamentally, the overlap between the services we provide and what is often on a digital economy is not very large.”
Ameera Shah, page 34 of the filed PDF · View the filing
Risks flagged
Fading CGHS price increase benefit for competitors from Q3 onwards, which Metropolis did not benefit from due to low CGHS exposure
p. 21
“But some of the other operators have got huge benefit which anyway will start fading away from Q3 onwards because last year Q3, you know, the CGHS rates got increased.”
Surendran Chemmenkotil, page 21 of the filed PDF · View the filing
Margin dilution from acquiring breakeven businesses like Core Diagnostics in the near term
p. 9
“That while it's showing it's suppressing the margin by 1.5%, obviously as the losses of core have now gone and we've moved into profit-making zone that gap will keep narrowing as we move forward”
Ameera Shah, page 9 of the filed PDF · View the filing
High acquisition multiples paid by some private players without ability to integrate or realize synergies
p. 27
“We are seeing some private players who are just going and buying every business available, not thinking about the future, not having the ability to integrate, and buying them at 18 multiple, 19 multiple”
Ameera Shah, page 27 of the filed PDF · View the filing
Advanced radiology (MRI/CT) has different, less favorable ROIC and governance considerations for the illness segment
p. 31
“we fully understand that the advanced radiology bit, the ROCs are very different.”
Ameera Shah, page 31 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.
Continue reading
- Metropolis Healthcare Ltd: filed results and exchange announcements
- Q1 FY27 results for every company Parakho holds
More Q1 FY27 earnings calls, in alphabetical order